NAGE vs USNA
Niagen Bioscience, Inc. and Usana Health Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NAGE | USNA |
|---|---|---|
| Revenue | $129.4M | $925.3M |
| Net income | $17.4M | $10.8M |
| Gross margin | 64.3% | 78.3% |
| Net margin | 13.4% | 1.2% |
| Return on equity | 28.3% | 2.0% |
| Diluted EPS | $0.20 | $0.58 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-21.2M | $8.5M |
| Equity | $76.5M | $533.1M |
| Net debt / equity | — | — |
| Current ratio | 4.86× | 2.24× |
| Revenue CAGR 5y | 16.9% | −4.0% |
| Profit CAGR 5y | — | −38.7% |
USNA bills 7.1× the revenue of NAGE, and NAGE keeps more of each dollar of revenue as profit (13.4% against 1.2%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | NAGE | USNA |
|---|---|---|
| FY2025 | $129.4M | $925.3M |
| FY2024 | $99.6M | $854.5M |
| FY2023 | $83.6M | $921.0M |
| FY2022 | $72.0M | $998.6M |
| FY2021 | $67.4M | $1.2B |
| FY2020 | $59.3M | $1.1B |
| FY2019 | $46.3M | $1.1B |
| FY2018 | $31.6M | $1.2B |
| FY2017 | $21.2M | $1.0B |
| FY2016 | $21.7M | $1.0B |
Net income by year
Bottom line
| Fiscal year | NAGE | USNA |
|---|---|---|
| FY2025 | $17.4M | $10.8M |
| FY2024 | $8.6M | $42.0M |
| FY2023 | $-4.9M | $63.8M |
| FY2022 | $-16.5M | $69.3M |
| FY2021 | $-27.1M | $116.5M |
| FY2020 | $-19.9M | $124.7M |
| FY2019 | $-32.1M | $100.5M |
| FY2018 | $-33.3M | $126.2M |
| FY2017 | $-11.4M | $62.5M |
| FY2016 | $-2.9M | $100.0M |
Advertisement
AdSense · Rectangle 336×280
More in this industry